Clinical Trial Update: Duration of Treatment With Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell Carcinoma

View source ↗

Summary

A completed clinical trial update evaluates the optimal duration of tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Snippet

Sponsor: Bayer | Conditions: Renal Cell Carcinoma | Status: COMPLETED